A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
NCT04976777
Completed
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator. This purpose of this study is to show that the updated DEX PS DDS Applicator works in adult participants with macular edema due to retinal diseases. The DEX PS DDS is approved for the treatment of macular edema. Participants will be placed into 1 of 2 groups, called treatment arms. Each group receives the same trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2023
Locations: Global Research Management /ID# 238944, Glendale, California +6 locations
Conditions: Macular Edema
Register for Updates
A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
NCT04945824
Terminated
This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in tears. Each subject's participation is expected to last for approximately 1 month from the DEXTENZA insertion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2023
Locations: Ocular Therapeutix, Inc., Sioux Falls, South Dakota
Conditions: Healthy
Register for Updates
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
NCT03439280
Completed
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2023
Locations: City of Hope - Duarte, Duarte, California +6 locations
Conditions: Relapsed/Refractory, Multiple Myeloma
Register for Updates
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
NCT05493618
Withdrawn
This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2023
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia +2 locations
Conditions: Multiple Myeloma, Refractory
Register for Updates
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
NCT02628704
Withdrawn
Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib (Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2023
Locations: James R. Berenson MD, Inc, West Hollywood, California +1 locations
Conditions: Multiple Myeloma
Register for Updates
Selinexor Treatment of Refractory Myeloma
NCT02336815
Completed
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2023
Locations: University of Alabama, Birmingham, Alabama +60 locations
Conditions: Multiple Myeloma
Register for Updates
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
NCT03252600
Unknown
This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement. Drugs used in chemotherapy, such as lenalidomide, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2023
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +4 locations
Conditions: Recurrent Primary Amyloidosis
Register for Updates
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
NCT04130802
Completed
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. The primary objective is to evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is to evaluate the optimal dosing frequency (once a day \[QD\] or twice a day \[BID\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2023
Locations: Medical cennre, Petaluma, California +3 locations
Conditions: Inflammation Corneal, Pain, Postoperative
Register for Updates
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
NCT02186834
Completed
The main purpose of this study is to determine the recommended doses of selinexor in combination with liposomal doxorubicin and dexamethasone for patients with relapsed and refractory myeloma. In addition, the study will assess whether this combination with effective for patients with multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/29/2022
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +1 locations
Conditions: Multiple Myeloma
Register for Updates
Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes
NCT02469519
Completed
This trial hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity in pregnant women with pre-labor premature rupture of the membranes.
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
12/14/2022
Locations: University of South Alabama Medical Center, Mobile, Alabama +8 locations
Conditions: Premature Birth
Register for Updates
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
NCT03481556
Terminated
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2022
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +15 locations
Conditions: Multiple Myeloma
Register for Updates
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01005914
Terminated
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving pegaspargase together with combination chemotherapy and to see how well it works in treating patients with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/13/2022
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Leukemia
Register for Updates